BioCentury

7:00 AM GMT, Jul 19, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

SF1126: Updated Phase I data

Updated data from 33 evaluable patients in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly SF1126

Read the full 199 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.